2021
Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC
Doroshow DB, Wei W, Gupta S, Zugazagoitia J, Robbins C, Adamson B, Rimm DL. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC. Journal Of Thoracic Oncology 2021, 16: 2139-2143. PMID: 34455068, PMCID: PMC8612948, DOI: 10.1016/j.jtho.2021.07.032.Peer-Reviewed Original ResearchConceptsPD-L1 tumor proportion scoreTumor proportion scoreHigh PD-L1 tumor proportion scoreOverall survivalNonsquamous histologySquamous NSCLCNonsquamous NSCLCPredictive biomarkersProportion scoreDeath ligand 1 (PD-L1) tumor proportion scoreElectronic health record-derived databaseFirst-line pembrolizumab therapyPD-1 expression levelsPD-L1 expression levelsCommunity oncology clinicsMedian OS differenceSingle-agent pembrolizumabImmune checkpoint inhibitorsImproved overall survivalMedian overall survivalPrimary end pointFirst-line pembrolizumabFirst-line therapyPD-L1 expressionPD-L1 testing
2020
Delivery of cancer survivorship education to community health care professionals.
Pariser A, Brita J, Harrigan M, Capozza S, Khairallah A, Sanft T. Delivery of cancer survivorship education to community health care professionals. Journal Of Clinical Oncology 2020, 38: 11032-11032. DOI: 10.1200/jco.2020.38.15_suppl.11032.Peer-Reviewed Original ResearchAdvanced practice providersProject ECHO modelCancer survivorship educationSurvivorship careCancer survivorsSurvivorship educationCommunity health care professionalsCommunity oncology clinicsImproved provider knowledgeCancer survivorship careHealthy lifestyle behaviorsStandard of careHealth care professionalsPrevention careOncology providersMedical oncologistsOncology clinicOncology careLifestyle behaviorsProvider knowledgePractice providersCare outcomesCare professionalsRadiation oncologistsPatient care
2017
Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network
Kwak YE, Stein SM, Lim JK. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. Digestive Diseases And Sciences 2017, 63: 61-71. PMID: 29177849, DOI: 10.1007/s10620-017-4850-1.Peer-Reviewed Original ResearchConceptsCommunity oncology clinicsCommunity teaching hospitalHBV screening rateOncology clinicTeaching hospitalHBV infectionScreening ratesCancer chemotherapyUniversity HospitalChronic hepatitis B virus infectionHepatitis B virus infectionHepatitis B Virus ScreeningHBV reactivation riskChronic HBV infectionB virus infectionHBV core antibodyHBV surface antigenAdult cancer patientsRisk of reactivationHospital networkLarge university hospitalCore antibodyHBV exposureHBV screeningBackgroundCancer patients
2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
OH W, McDERMOTT D, PORTA C, LEVY A, ELAIDI R, SCOTTE F, HAWKINS R, CASTELLANO D, BELLMUNT J, RHA S, SUN J, NATHAN P, FEINBERG B, SCOTT J, McDERMOTT R, AHN J, WAGSTAFF J, CHANG Y, OU Y, DONNELLAN P, HUANG C, McCAFFREY J, CHIANG P, CHUANG C, KORVES C, NEARY M, DIAZ J, MEHMUD F, DUH M. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. International Journal Of Oncology 2013, 44: 5-16. PMID: 24247547, PMCID: PMC3867384, DOI: 10.3892/ijo.2013.2181.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAsiaBevacizumabCarcinoma, Renal CellDrug-Related Side Effects and Adverse ReactionsEuropeFemaleHumansIndolesKaplan-Meier EstimateMaleMiddle AgedNiacinamidePhenylurea CompoundsPyrrolesSorafenibSunitinibTreatment OutcomeUnited StatesConceptsBevacizumab patientsAdverse eventsTreatment modificationTreatment patternsTreatment durationGrade 3/4 adverse eventsAdvanced renal cell carcinomaSafety of sunitinibMedian treatment durationAdvanced RCC patientsFirst-line treatmentAngiogenesis inhibitor therapyKaplan-Meier analysisRenal cell carcinomaTertiary oncology centerAssociated with higher ratesMedical chart reviewCommunity oncology clinicsAdvanced RCCInhibitor therapyTreatment discontinuationDose reductionCell carcinomaRCC patientsBevacizumab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply